Drug Trial Radar · NCT05009836
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
412
Planned (sponsor's estimate)
Start
Sep 6, 2021
Primary completion
May 30, 2028
Study completion May 30, 2028
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions
- Non-small Cell Lung Cancer
Interventions
SavolitinibDrug
Savolitinib 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally
PlaceboDrug
Placebo 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally
OsimertinibDrug
Osimertinib 80 mg QD orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 17 months after the last patient enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong General Hospital
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.